41 results about "Laryngeal squamous cell carcinoma" patented technology

The invention discloses application of a non-coding RNA relevant to occurrence and development of laryngeal squamous cell carcinoma. The non-coding RNA is LOC100507599. According to the application, through combination of a high throughput sequencing technology with bioinformation analysis, it is found for the first time that expression of the LOC100507599 in a patient suffering from the laryngealsquamous cell carcinoma is up-regulated, and the conclusion is verified through further QPCR, which indicates that the LOC100507599 can serve as a molecular target to be applied to diagnosis and treatment of the laryngeal squamous cell carcinoma.

The invention discloses a laryngeal squamous cell carcinoma cartilage invasion model. The laryngeal squamous cell carcinoma cartilage invasion model comprises a laryngeal squamous cell carcinoma invasion in-vitro experimental model, a laryngeal squamous cell carcinoma cartilage invasion semi-vitro experimental model, and a laryngeal squamous cell carcinoma cartilage invasion in-vivo experimental model. A method comprises the following steps of: closing the cup bottom of a Transwell chamber by using a polycarbonate microporous filter membrane; artificially reconstructing a basement membrane Matrigel and coating on the filter membrane; putting the Transwell chamber into a culture hole after the Matrigel is in a gel state, irradiating for 2h by using ultraviolet rays, and sterilizing for later use; adding an RPMI1640 culture medium containing 10 percent calf serum into the lower chamber, uniformly adding Hep-2 cells of laryngeal squamous cell carcinoma into the upper chamber, culturing, softly wiping away the Matrigel gel and cells which are not infiltrated at the cup bottom, immobilizing by using ethanol, and dyeing by using crystal violet; and counting the number of member-penetrating cells and taking an average value, wherein the relative number of the member-penetrating cells represents the invasiveness. In the invention, the laryngeal squamous cell carcinoma cartilage invasion model can be effectively established; and the discussion of an invasion mechanism of laryngeal squamous cell carcinoma on cartilages plays an important role in preventing the metastasis and relapse of laryngeal squamous cell carcinoma and selecting effective personalized therapeutic schedules.

The invention provides application of LOC100505874 as a molecular marker in the diagnosis of laryngeal squamous cell carcinoma. It is shown through research that there is a significant difference in the expression of the LOC100505874 in the carcinoma tissue and para-carcinoma tissue of a patient with the laryngeal squamous cell carcinoma, and based on the difference, it is considered that the LOC100505874 can be used as the molecular marker for the diagnosis of the laryngeal squamous cell carcinoma. According to research results, a product capable of being used for the early diagnosis of the laryngeal squamous cell carcinoma is developed and is high in detection rate and suitable for clinical popularization.

The invention belongs to the technical fields of molecular diagnosis and molecular biology, and specifically relates to a screening method for a serum exosome marker of laryngeal squamous carcinoma and an application for an exosome source miR-941. The screening method comprises the following steps: screening serum exosome miRNAs which are differentially expressed between a laryngeal squamous carcinoma patient and a healthy control person through high-throughput sequencing, and selecting miRNAs which are up-regulated and expressed in the laryngeal squamous carcinoma patient and are high in expression quantity as candidate miRNAs; carrying out qRT-PCR verification on the candidate miRNAs in another group of expanded samples, and screening out a reference gene for qRT-PCR detection before verification; and analyzing the diagnosis efficiency of target miRNAs by adopting an ROC curve. The invention also provides a serum exosome miRNA marker miR-941 for the laryngeal squamous carcinoma. Thus, a new way is provided for minimally invasive diagnosis of the laryngeal squamous carcinoma; meanwhile, the serum exosome miRNA marker miR-941 can serve as a potential drug treatment target and has great clinical practical value.

The invention discloses a diagnostic marker and a therapeutic target for laryngeal squamous cell carcinoma. The diagnostic marker and the therapeutic target for laryngeal squamous cell carcinoma are MYOZ3, and belong to the technical field of new application of genes. According to the diagnostic marker and the therapeutic target disclosed by the invention, down-regulation of expression of the marker MYOZ3 in patients suffering from the laryngeal squamous cell carcinoma is firstly found; moreover, through up-regulated expression of the MYOZ3, the proliferation of cancer cells can be reduced, and the MYOZ3 is prompted to be as a target, the MYOZ3 can be used for realizing accurate treatment on the laryngeal squamous cell carcinoma.

The invention discloses an application of LOC100507599 to diagnosis of laryngeal squamous cell carcinoma. The content of LOC100507599 in cancer tissue of patients suffering from laryngeal squamous cell carcinoma has significant differences from that in Precancerous lesions. According to the differences, the patients suffering from laryngeal squamous cell carcinoma and the patients not suffering from the laryngeal squamous cell carcinoma can be distinguished. The invention further discloses a diagnosis product of the laryngeal squamous cell carcinoma, and the diagnosis product can realize the purpose of diagnosis of the laryngeal squamous cell carcinoms by detecting the LOC100507599 in tissue.

The invention discloses a molecular marker which can be used for diagnosing laryngeal squamous cell carcinoma. The marker is LOC100507002. By detecting the level of the LOC100507002 in the suspected diseased tissue of a subject, the invention can judge whether the subject suffers from laryngeal squamous cell carcinoma or not or whether the subject has the risk of suffering from laryngeal squamouscell carcinoma. According to the LOC100507002, a product for diagnosing laryngeal squamous cell carcinoma by detecting the content of the LOC100507002 can be developed, and the diagnosis product can be popularized and used clinically.

The invention relates to the application of miR-1207 and a target gene of the miR-1207 in detecting laryngeal squamous cell carcinoma. A high-throughput sequencing method is adopted to find genes withsignificant differential expression in laryngeal squamous cell carcinoma and adjacent tissues, and bioinformatics analysis is combined to select miR-1207-3p and the target gene KC6 and LINC00319 of the miR-1207 from alternative miRNA for RT-PCR verification, and the result shows that miR-1207-3p and the target gene of the miR-1207-3p have a good correlation with the laryngeal squamous cell carcinoma. The application of miR-1207 and the target gene of the miR-1207 in detecting laryngeal squamous cell carcinoma provide a novel important target for clinical diagnosis and treatment of the laryngeal squamous cell carcinoma.

The invention discloses application of long noncoding RNA (Ribonucleic Acid) in cancer diagnosis and treatment. The long noncoding RNA is LOC730101. The expression of the LOC730101 is subjected to upregulation in a laryngeal squamous cell carcinoma patient, the expression level of the LOC730101 can be detected to judge whether a subject suffers from the laryngeal squamous cell carcinoma or not, the expression of the LOC730101 can be subjected to down regulation to inhibit the proliferation and the migration of carcinoma cells, and a new target is provided for treating the laryngeal squamous cell carcinoma.

The invention relates to the technical field of molecular diagnosis, in particular to a kit for detecting laryngeal squamous cell carcinoma radiotherapy sensitivity related gene ATM and ATR gene mutation and an application of the kit. The kit consists of reagents for detecting expression quantities of VSTM2L, TSPAN8, RDH10, PRODH, PITX2, ODC1, MASP1, KLHDC8A, GPRC5D, CTAG2, CCL26 and ABCA13. According to the method, genes related to ATM and ATR mutation are screened by applying RNA sequencing, LASSO and binary classification Logistic regression, a Score is constructed, a threshold value corresponding to the Score in the laryngeal squamous cell carcinoma is obtained through ROC analysis, and the method can be used for predicting ATM and ATR gene mutation in the laryngeal squamous cell carcinoma. The specific gene mutation related to the laryngeal squamous cell carcinoma radiotherapy sensitivity is predicted by utilizing the expression quantity of a gene composition, and verification shows that the detection method has the advantages of simplicity and convenience in operation, high accuracy and good specificity, and has a very good application prospect.

The invention discloses a laryngeal squamous cell carcinoma molecular marker hsa_circ-0018169 as well as a detection method and application thereof. The nucleotide sequence of the laryngeal squamous cell carcinoma molecular marker hsa_circ-0018169 is as shown in SEQ ID NO:1. The laryngeal squamous cell carcinoma molecular marker hsa_circ_0018169 is applied to detection and prognosis of laryngeal squamous cell carcinoma. The laryngeal squamous cell carcinoma molecular marker hsa_circ-0018169 is applied to the preparation of a laryngeal squamous cell carcinoma auxiliary diagnosis kit. The invention provides a sequence of siRNA (small interfering ribonucleic acid) of the hsa_circ-0018169. The siRNA of the hsa_circ-0018169 is used for knocking down the expression of the hsa_circ-0018169 in laryngeal squamous cell carcinoma cells, has the effect of inhibiting malignant proliferation of the laryngeal squamous cell carcinoma cells, and is used for preparing laryngeal squamous cell carcinoma drugs; a primer of the hsa_circ-0018169 is high in specificity and stable in result, and a basis is provided for the biological research of the hsa_circ-0018169; and the siRNA designed by the inventioncan effectively reduce the expression quantity of hsa_circ-0018169, and has the characteristics of high efficiency and quick action.

The invention discloses a CMYA5 gene and an expressed product of the CMYA5 gene in application of a laryngeal squamous cell carcinoma. Low expression of CMYA5 is presented in a laryngeal squamous cell carcinoma tissue. By increasing the expression of the CMYA5, cell proliferation and invasion of the laryngeal squamous cell carcinoma can be reduced. The sensibility and specificity of diagnosing of the laryngeal squamous cell carcinoma are greatly improved, and meanwhile a new target spot is provided for precise treatment of the laryngeal squamous cell carcinoma.

A eukaryon recombinant plasmid is constructed by a eukaryotic vector and a CY-FBXL20 segment in the nucleotide sequence of human FBXL20 gene shown in SEQ ID NO.1 in a sequence table, and the CY-FBXL20 segment is a nucleotide sequence from 10045bp to 10063bp in initiator codon downstream. A preparation process of the eukaryon recombinant plasmid comprises the following steps of firstly, obtaining an RNAi segment of the CY-FBXL20 segment in the human FBXL20 gene by means of a ribonucleic acid (RNA) solid phase synthesis method; secondly, inserting the RNAi segment with respective restriction enzyme cutting sites of BamI and BbsI of the CY-FBXL20 segment into the eukaryotic vector to construct the eukaryon recombinant plasmid, transforming the eukaryon recombinant plasmid into competence bacteria for culturing, and screening out clones containing correct inserted segments; and thirdly, extracting the constructed eukaryon recombinant plasmid by means of an alkaline lysis method, analyzing the constructed eukaryon recombinant plasmid by means of a restriction enzyme restriction enzyme map, and performing deoxyribonucleic acid (DNA) sequence analysis. The eukaryon recombinant plasmid can be applicable to the preparation of drugs for curing laryngeal squamous cell carcinoma.

The invention discloses application of LOC158435 as a biomarker for diagnosing and treating a laryngeal squamous cell carcinoma. QPCR (quantitative polymerase chain reaction) and an in vitro cell experiment prove that the LOC158435 is closely related to the diagnosis and the treatment of the laryngeal squamous cell carcinoma, and therefore, a research result of the invention provides a new diagnosis method and treatment method for clinical application.

The invention discloses a non-coding RNA closely related to laryngeal squamous cell carcinoma, and the non-coding RNA is LOC100506860. Experiments of the invention prove that the LOC100506860 is closely related to diagnosis and treatment of the laryngeal squamous cell carcinoma, so that the LOC100506860 can be used as a diagnosis and treatment marker to be applied clinically.

The invention discloses a laryngeal squamous cell carcinoma cartilage invasion model. The laryngeal squamous cell carcinoma cartilage invasion model comprises a laryngeal squamous cell carcinoma invasion in-vitro experimental model, a laryngeal squamous cell carcinoma cartilage invasion semi-vitro experimental model, and a laryngeal squamous cell carcinoma cartilage invasion in-vivo experimental model. A method comprises the following steps of: closing the cup bottom of a Transwell chamber by using a polycarbonate microporous filter membrane; artificially reconstructing a basement membrane Matrigel and coating on the filter membrane; putting the Transwell chamber into a culture hole after the Matrigel is in a gel state, irradiating for 2h by using ultraviolet rays, and sterilizing for later use; adding an RPMI1640 culture medium containing 10 percent calf serum into the lower chamber, uniformly adding Hep-2 cells of laryngeal squamous cell carcinoma into the upper chamber, culturing, softly wiping away the Matrigel gel and cells which are not infiltrated at the cup bottom, immobilizing by using ethanol, and dyeing by using crystal violet; and counting the number of member-penetrating cells and taking an average value, wherein the relative number of the member-penetrating cells represents the invasiveness. In the invention, the laryngeal squamous cell carcinoma cartilage invasion model can be effectively established; and the discussion of an invasion mechanism of laryngeal squamous cell carcinoma on cartilages plays an important role in preventing the metastasis and relapse of laryngeal squamous cell carcinoma and selecting effective personalized therapeutic schedules.

The invention discloses a plasma gene detection kit for early diagnosis of laryngeal squamous cell carcinoma (LSCC). By adopting the plasma gene detection kit, the accuracy of combined prediction of the LSCC with has-miR-544a, has-miR-4726 and hsa-miR-135a-5p is found to be 91.67% (88 / 96); the accuracy of combined prediction of the LSCC with hsa-miR-544a, hsa-miR-4726 and hsa-miR-2278 is 90.63% (87 / 96); and the accuracy of combined prediction of the LSCC with hsa-miR-544a, hsa-miR-636 and hsa-miR-597-5p is 94.79% (91 / 96), and the diagnostic accuracy is high.

The present invention discloses the application of miR-1207 and its target gene in detecting laryngeal squamous cell carcinoma, and the target gene is LOC339685 or LOC400706. The invention discloses the application of a reagent for detecting LOC339685 or LOC400706 in preparing a product for diagnosing laryngeal squamous cell carcinoma, and also discloses the application of LOC339685 or LOC400706 in preparing a drug for treating laryngeal squamous cell carcinoma.

The invention provides a method for preparing a human laryngeal squamous cell carcinoma related gene SKA3 eukaryotic expression protein monomer. The method includes inserting a human laryngeal squamous cell carcinoma related gene SKA3 into a PGEX-4T-1 carrier to obtain a PGEX-4T-1-SKA3 prokaryotic expression carrier; obtaining a fusion fragment GST-SKA3 PCR and inserting the segment into a pCMV-HAcarrier to obtain an SKA3 eukaryotic expression carrier pCMV-HA-GST-SKA3 with HA and GST labels; cultivating a laryngeal squamous carcinoma cell Hep-2 transfected with the eukaryotic expression and then conducting purification to obtain a recombinant GST fusion protein. The method specifically includes the following steps: (1) construction and verification of the prokaryotic expression carrier PGEX-4T-1-SKA3; (2) construction and verification of the eukaryotic expression carrier pCMV-HA-GST-SKA3; (3) eukaryotic expression and purification in laryngeal squamous cell carcinoma Hep-2 cells. TheGST label can increase the solubility and the expression quantity of the protein expression. The eukaryotic expression carrier pCMV-HA is utilized to expresses the protein and forms a stable disulfidebond during the expression to correctly fold the expressed protein and perform complex glycosylation modification on the expressed protein. The protein activity is close to the native protein, and the endotoxin is not required to be removed.

The present invention discloses a laryngeal squamous cell carcinoma molecular marker hsa_circ_0004547 and a detection method and an application thereof, and belongs to the technical field of biology.A location of the provided laryngeal squamous cell carcinoma molecular marker hsa_circ_0004547 on the genome is: chr22:29517344-29521404 and has a nucleotide sequence shown in SEQ ID NO:1. The expression level of the hsa_circ_0004547 is up-regulated in tissues of patients with laryngeal squamous cell carcinoma. Back-to-back primers of the hsa_circ_0004547 in real-time fluorescence quantification in a method for detecting the expression of the laryngeal squamous cell carcinoma molecular marker are F1: 5'-GGCAGGAATTGCAGCGAGAA-3'; and R1: 5'-AAAGCAGCAGGATGGTGGC-3'. The present invention providesa siRNA sequence of the hsa_circ_0004547. The siRNA of the hsa_circ_0004547 is used to knock down the expression of the hsa_circ_00004547 in laryngeal squamous cell carcinoma cells, has an inhibitoryeffect on migration ability of the laryngeal squamous cell carcinoma cells, and can be used to prepare chemotherapy drugs for the laryngeal squamous cell carcinoma. The screened out hsa_circ_0004547 can be used as a new molecular marker for an early diagnosis of the laryngeal squamous cell carcinoma and detection of the molecular marker can be used for simple and quick initial diagnosis of the laryngeal squamous cell carcinoma. The designed siRNA can effectively reduce the expression level of the hsa_circ_0004547 and has the characteristics of high efficiency and rapid action.

The invention discloses molecules for early diagnosis and treatment of cancer. The molecules are LOC442028. The invention also discloses a reagent and reagent kit for detecting the molecules. Throughresearch, the inventor finds that the molecules can also become a medicine target for treating laryngeal squamous cell carcinoma. The research findings provide a theoretical basis for clinical diagnosis of the laryngeal squamous cell carcinoma and treatment of the laryngeal squamous cell carcinoma.

The invention belongs to the technical field of serum endogenous small molecule application, and particularly relates to an application of serum endogenous small molecules in evaluating a differentiation degree of laryngeal cancer tumor cells. According to the application of the serum endogenous small molecules in evaluating the differentiation degree of the laryngeal cancer tumor cells, the serumendogenous small molecules refer to eight laryngeal cancer biological metabolism markers, which are screened out by means of performing LC-MS metabonomics analysis on the basis of a laryngeal squamous cell carcinoma serum sample; and the eight laryngeal cancer biological metabolism markers specifically include a metabolite L-Carnitine, a metabolite 9-Decenolicarnitine, a metabolite Glycocholic acid, a metabolite Oleoyl glycinine, a metabolite cis-5-Tetronecenolicarnitine, a metabolite 3, 5-Tetradecadiencarnitine, a metabolite 2-Hydroxyadipic acid and a metabolite Sphingosine 1-phosphate, andthe differentiation degree of the laryngeal cancer tumor cells is evaluated according to content changes of the eight serum endogenous small molecules. According to the laryngeal cancer differentiation degree evaluation method based on serum metabonomics, a serum sample is adopted, the cost is low, and damage to the body is small.

The invention discloses a molecular marker related to incidence and development of laryngeal carcinoma. The molecular marker is LOC100507437. According to the molecular marker related to incidence anddevelopment of laryngeal carcinoma, QPCR research proves that expression of LOC100507437 in laryngeal squamous cell carcinoma tissue is significantly up-regulated compared with those of control groups, and according to the differential expression characteristic of LOC100507437, LOC100507437 can be used as the molecular marker for diagnosing laryngeal squamous cell carcinoma. Moreover, an in-vitroexperiment proves that expression of LOC100507437 is related to proliferation and migration of laryngeal squamous cell carcinoma so that LOC100507437 can be used as a molecular target for treating laryngeal squamous cell carcinoma.

The invention relates to a kit for predicting susceptibility of laryngeal squamous cell carcinoma. The kit comprises the following components: an STR-1 (Short tandem repeats) primer, an STR-2 primer,an STR-3 primer, an STR-4 primer, an STR-5 primer, an STR-6 primer, and also comprises a PCR (Polymerase Chain Reaction) amplification reaction solution, an LIZ-500 molecular weight internal lane standard, and deionized formamide. The kit for predicting susceptibility of laryngeal squamous cell carcinoma provided by the invention can be used for diagnosis and susceptibility prediction of laryngealsquamous cell carcinoma. The invention also provides a system for predicting susceptibility of laryngeal squamous cell carcinoma.

The invention discloses a blood plasma gene detection kit for early diagnosis of laryngeal squamous cell carcinoma. The invention finds out that the accuracy of combined prediction of hsa-miR-544a, hsa-miR-4726 and hsa-miR-135a-5p is 91.67 percent (88 / 96); the accuracy of the combined prediction of the hsa-miR-544a, the hsa-miR-4726 and hsa-miR-2278 is 90.63 percent (87 / 96); the accuracy of the combined prediction of the hsa-miR-544a, hsa-miR-636 and hsa-miR-597-5p is 94.79 percent (91 / 96); the diagnosis accuracy is high.

The invention discloses a saliva gene detection kit for early diagnosis of laryngeal squamous cell carcinoma. The accurate rate of performing combined diagnosis on LSCC by using hsa-miR-544a, has-miR-4726 and has-miR-154-3p in the saliva is 96.88 percent (93-96); the accurate rate of performing combined diagnosis on LSCC by using hsa-miR-544a, has-miR-4726 and has-miR-655-5p in the saliva is 92.71percent (89 / 96); the accurate rate of performing combined diagnosis on LSCC by using hsa-miR-544a, has-miR-4726 and has-miR-552-3p in the saliva is 95.83 percent (92 / 96); and the diagnosis accurate rate is high.

The invention discloses application of miR-1207 and a target gene thereof in detection of laryngeal squamous cell carcinoma. The target gene is LOC339685 or LOC400706. The invention discloses application of a reagent for detecting LOC339685 or LOC400706 in preparation of a product for diagnosing laryngeal squamous cell carcinoma, and also discloses application of LOC339685 or LOC400706 in preparation of a medicine for treating laryngeal squamous cell carcinoma.

The invention discloses a saliva genetic detection kit for early diagnosis of laryngeal squamous cell carcinoma. The accuracy of combined diagnosis of LSCC with has-miR-544a, has-miR-4726 and has-miR-154-3p in saliva is 96.88% (93 / 96); the accuracy of combined diagnosis of the LSCC with has-miR-544a, hsa-miR-4726 and has-miR-655-5p in the saliva is 92.71% (89 / 96); the accuracy of combined diagnosis of the LSCC with has-miR-544a, has-miR-4726 and has-miR-552-3p in saliva is 95.83% (92 / 96), and the diagnosis accuracy is high.

The invention discloses a circular RNA molecular marker for the laryngeal squamous cell carcinoma, and a detection method and application of the circular RNA molecular marker. The nucleotide sequenceof the circular RNA molecular marker has_circ_0000033 for the laryngeal squamous cell carcinoma is disclosed by SEQ ID NO.1. The expression level of the has_circ_0000033 in the carcinoma tissues of alaryngeal squamous cell carcinoma patient is up-regulated, and the has_circ_0000033 is applied to preparation of an auxiliary diagnosis kit for the laryngeal squamous cell carcinoma. The detection method, which is provided by the invention, of a laryngeal squamous cell carcinoma molecular marker quantity carries out real-time quantitative PCR detection by a fluorescent dye method, and a back-to-back primer designed by aiming at the detection method is disclosed by SEQ ID NO.2-3. The invention provides a specific siRNA sequence of the targeted has_circ_0000033, and the siRNA is used for knocking out has_circ_0000033 expression in a laryngeal squamous cell carcinoma cell line and performing a biological function of inhibiting the multiplication capacity of the laryngeal squamous cell carcinoma cell line. The laryngeal squamous cell carcinoma molecular marker has_circ_0000033 disclosed by the invention has an application prospect of simply and quickly making a laryngeal squamous cell carcinoma auxiliary diagnosis. The siRNA sequence designed by the invention can effectively lower the expression quantity of the has_circ_0000033, and has the characteristics of being specific and quick in acting.